from the PGLA board on Yahoot. Very good stuff. -------------------------------------------
Professional stock market participants recognise Thomson Reuters as a respected research organisation.
Under Pharma matters in Thomson Reuters most recent issue of “THE ONES TO WATCH” they review the five most promising drugs to enter each new phase of clinical development, between January and March 2008 (issued May 19th, 2008).
Progen with its PI-88 is on the top of the list (see pg. 4) http://www.thomsonpharma.com/media/pdfs/...
“Expert review from Thomson Reuters of the most promising drugs changing clinical phase, receiving approval and launched this quarter, based on the strategic data and insight of Thomson Pharma®, the world’s leading pharmaceutical competitive intelligence solution”.
The five most promising drugs entering Phase III trials
"Turning to the drugs entering phase III this quarter, PI-88 is under development by Progen for the potential treatment of cancers, including solid tumors, multiple myeloma and non-small-cell lung cancer. The drug has a first-in-class mechanism as a heparan sulfate mimetic. Its anti-tumor activity is based on inhibition of two biological processes — angiogenesis and metastasis.
Progen reported positive data from phase II trials in February 2008, indicating that PI-88 increases time to tumor recurrence by 76% in patients with post-operative primary hepatocellular carcinoma (HCC). Subjects treated with 160 mg of PI-88 had a 30-week delay in tumor recurrence compared with 17 weeks for those who did not receive the drug. The company also reported high rates of febrile neutropenia.
Global phase III trials for HCC were initiated in March 2008, with the goal of gathering data for regulatory filing. The drug was awarded FDA Fast Track and EC Orphan Drug status for HCC in September 2007". .......................................
This “most promising drug” status is excellent validation from an independent source of Progen’s PI-88 science. Note that PI-88 is the only cancer drug listed in the PhaseIII section
Progen holders should be pleased with this recognition.
An ardent Progen holder brought this publication to my attention. Also Thank-you to Mr Google <:)
PGL Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
